Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 28, 2015 7:00 AM ET

Biotechnology

Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

16745 West Bernardo Drive

Suite 200

San Diego, CA 92121

United States

Founded in 2005

25 Employees

Phone:

858-376-2600

Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $419.5K
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Age: 56
Total Annual Compensation: $283.1K
Compensation as of Fiscal Year 2013.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. Announces Clinical Results At EASL Meeting Support Emricasan Registration Pathway in NASH

Conatus Pharmaceuticals Inc. announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress™ 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26, 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure (ACLF), and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH), are addressed in two late-breaker posters: Poster #LP35, entitled A placebo-controlled, multicenter, double-blind, randomised, pharmacokinetic and pharmacodynamic trial of emricasan (IDN-6556) in subjects with acute-on-chronic liver failure (ACLF); and poster #LP37, entitled A placebo-controlled, multicenter, double-blind, randomised trial of emricasan (IDN-6556) in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. A third poster addresses results from the company's Phase 1 trial in patients with mild, moderate and severe hepatic impairment and the company's Phase 1 trial in patients with severe renal impairment: Poster #P0396, entitled Emricasan, a potent pan-caspase inhibitor, rapidly reduces caspase activity and biomarkers of apoptosis in patients with hepatic impairment but not in healthy volunteers: implications for safety, selectivity and mechanism of action. The company intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan. This population already represents a high unmet medical need that is expected to continue growing in the years ahead. Importantly, three validated surrogate markers of mortality risk were identified for this segment of liver disease patients in a manuscript co-authored by the American Association for the Study of Liver Diseases (AASLD) and the U.S. Food and Drug Administration (FDA), and accepted in January 2015 for publication in the scientific journal Hepatology: Model for End-stage Liver Disease (MELD) score; Child-Pugh-Turcotte (CPT) score; and Hepatic venous pressure gradient (HVPG).

Conatus Pharmaceuticals Announces Top-Line Results from Phase 2 Double-Blind, Placebo-Controlled Clinical Trial of Emricasan

On March 26, 2015, Conatus Pharmaceuticals Inc. announced top-line results from the Company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically significant (p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing compared to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of approximately 39% in the emricasan treatment arm and approximately 14% in the placebo arm were similar to results observed in previous trials. Elevated baseline levels of three key serum biomarkers caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18, and caspase 3/7 also showed statistically significant reductions from baseline in emricasan-treated patients at Day 28. The baseline elevation in cCK18 confirmed that the underlying targets of emricasan's mechanism, apoptosis and inflammation, which are believed to drive liver disease progression, were engaged in the NAFLD/NASH patients in this trial. A reduction from baseline in cCK18 at Day 28 of approximately 30% in the emricasan treatment arm and an increase from baseline of approximately 4% in the placebo arm were similar to results observed in previous trials. The reduction in serum cCK18 levels demonstrated that emricasan can effectively reduce inflammation and elevated levels of apoptosis in NAFLD/NASH patients. These results were consistent with data obtained from the Company's previous clinical trials in other liver disease patient populations.

Conatus Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM

Conatus Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Riverside Therapeutics Inc. United States
Tandem Medical, Inc. United States
Kytogenics Pharmaceutical, Inc. United States
Grifols USA, LLC United States
LaserGen, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Conatus Pharmaceuticals Inc., please visit www.conatuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.